Shares of Sensus Healthcare Inc (NASDAQ:SRTS) have been given an average recommendation of “Buy” by the eight ratings firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $12.25.
Several equities research analysts recently weighed in on the company. Maxim Group boosted their target price on Sensus Healthcare from $9.00 to $10.00 and gave the stock a “buy” rating in a report on Wednesday, September 19th. HC Wainwright began coverage on Sensus Healthcare in a report on Monday, August 27th. They set a “buy” rating and a $14.00 price target for the company. Roth Capital began coverage on Sensus Healthcare in a report on Wednesday, August 1st. They set a “buy” rating and a $12.50 price target for the company. Northland Securities lowered Sensus Healthcare from an “outperform” rating to a “market perform” rating in a report on Monday, October 15th. Finally, B. Riley began coverage on Sensus Healthcare in a report on Wednesday, September 26th. They set a “buy” rating and a $12.50 price target for the company.
SRTS opened at $6.61 on Friday. Sensus Healthcare has a twelve month low of $4.91 and a twelve month high of $8.88. The company has a debt-to-equity ratio of 0.39, a current ratio of 3.80 and a quick ratio of 3.49. The company has a market capitalization of $98.76 million, a P/E ratio of -23.61 and a beta of 0.61.
Sensus Healthcare (NASDAQ:SRTS) last posted its earnings results on Thursday, November 1st. The company reported ($0.03) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.07) by $0.04. Sensus Healthcare had a negative return on equity of 22.68% and a negative net margin of 10.21%. The firm had revenue of $6.33 million during the quarter, compared to analyst estimates of $5.73 million. Equities analysts expect that Sensus Healthcare will post -0.17 earnings per share for the current year.
Several hedge funds have recently modified their holdings of the company. AWM Investment Company Inc. lifted its holdings in shares of Sensus Healthcare by 34.6% during the third quarter. AWM Investment Company Inc. now owns 661,938 shares of the company’s stock worth $5,547,000 after buying an additional 170,000 shares during the last quarter. Perkins Capital Management Inc. lifted its holdings in shares of Sensus Healthcare by 60.7% during the third quarter. Perkins Capital Management Inc. now owns 396,836 shares of the company’s stock worth $3,325,000 after buying an additional 149,950 shares during the last quarter. Renaissance Technologies LLC lifted its holdings in shares of Sensus Healthcare by 141.1% during the second quarter. Renaissance Technologies LLC now owns 27,488 shares of the company’s stock worth $200,000 after buying an additional 16,088 shares during the last quarter. BlackRock Inc. acquired a new position in shares of Sensus Healthcare during the second quarter worth approximately $164,000. Finally, Paradigm Capital Management Inc. NY acquired a new position in shares of Sensus Healthcare during the second quarter worth approximately $152,000. Institutional investors own 8.18% of the company’s stock.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Further Reading: Understanding each part of a balance sheet
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.